Search Results - "Stange, E. F."

Innate immune dysfunction in inflammatory bowel disease by Gersemann, M., Wehkamp, J., Stange, E. F.

“…  Gersemann M, Wehkamp J, Stange EF (Robert Bosch Hospital, Stuttgart; Dr. Margarete Fischer‐Bosch Institute of Clinical Pharmacology, Stuttgart and…”
Get full text

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management by Dignass, A., Van Assche, G., Lindsay, J.O., Lémann, M., Söderholm, J., Colombel, J.F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., Hommes, D.W., Michetti, P., O'Morain, C., Öresland, T., Windsor, A., Stange, E.F., Travis, S.P.L.

Get full text

Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2 by Schlee, M, Harder, J, Köten, B, Stange, E.F, Wehkamp, J, Fellermann, K

“…Recent evidence suggests that probiotic bacteria may stabilize gut barrier function via induction of anti-microbial peptides such as defensins. This study…”
Get full text

European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis by Stange, E F, Travis, S P L, Vermeire, S, Beglinger, C, Kupcinkas, L, Geboes, K, Barakauskiene, A, Villanacci, V, Von Herbay, A, Warren, B F, Gasche, C, Tilg, H, Schreiber, Stefan W, Schölmerich, J, Reinisch, W

“…[...]expert opinion is included where appropriate. Inflammation related markers are therefore detected from the serum or the stool. [...]more reliable…”
Get full text

Short‐term efficacy of tacrolimus in steroid‐refractory ulcerative colitis – experience in 130 patients by Schmidt, K. J., Herrlinger, K. R., Emmrich, J., Barthel, D., Koc, H., Lehnert, H., Stange, E. F., Fellermann, K., Büning, J.

“…Summary Background Steroid‐refractory ulcerative colitis (UC) remains a challenging condition warranting surgery upon failure of pharmacological treatment…”
Get full text

European evidence based consensus on the diagnosis and management of Crohn’s disease: current management by Travis, S P L, Stange, E F, Lémann, M, Öresland, T, Chowers, Y, Forbes, A, D’Haens, G, Kitis, G, Cortot, A, Prantera, C, Marteau, P, Colombel, J-F, Gionchetti, P, Bouhnik, Y, Tiret, E, Kroesen, J, Starlinger, M, Mortensen, N J

“…This second section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns treatment of active…”
Get full text

NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression by Wehkamp, J, Harder, J, Weichenthal, M, Schwab, M, Schäffeler, E, Schlee, M, Herrlinger, K R, Stallmach, A, Noack, F, Fritz, P, Schröder, J M, Bevins, C L, Fellermann, K, Stange, E F

“…Background: Mutations in NOD2, a putative intracellular receptor for bacterial peptidoglycans, are associated with a subset of Crohn’s disease but the…”
Get full text

European evidence-based Consensus on the management of ulcerative colitis: Current management by Travis, S P L, Stange, E F, Lémann, M, Oresland, T, Bemelman, W A, Chowers, Y, Colombel, J F, D'Haens, G, Ghosh, S, Marteau, P, Kruis, W, Mortensen, N J McC, Penninckx, F, Gassull, M

Get full text

Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus by HERRLINGER, K. R., BARTHEL, D. N., SCHMIDT, K. J., BÜNING, J., BARTHEL, C. S., WEHKAMP, J., STANGE, E. F., FELLERMANN, K.

“…Aliment Pharmacol Ther 31, 1036–1041 Summary Background  The calcineurin inhibitor tacrolimus and the anti‐TNF‐antibody infliximab are established options in…”
Get full text

Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506) by Fellermann, K, Ludwig, D, Stahl, M, David-Walek, T, Stange, E F

“…Steroid treatment failure in acute Crohn's disease and ulcerative colitis frequently necessitates surgical intervention. Several alternative therapeutic…”
Get full text

ABCB1 Single‐Nucleotide Polymorphisms Determine Tacrolimus Response in Patients With Ulcerative Colitis by Herrlinger, KR, Koc, H, Winter, S, Teml, A, Stange, EF, Fellermann, K, Fritz, P, Schwab, M, Schaeffeler, E

“…Tacrolimus (Tac) is effective in the treatment of steroid‐refractory ulcerative colitis (UC); however, nonresponse and unpredictable side effects are major…”
Get full text

Paneth cell α-defensins HD-5 and HD-6 display differential degradation into active antimicrobial fragments by Ehmann, D., Wendler, J., Koeninger, L., Larsen, I. S., Klag, T., Berger, J., Marette, A., Schaller, M., Stange, E. F., Malek, N. P., Jensen, B. A. H., Wehkamp, J.

“…Antimicrobial peptides, in particular α-defensins expressed by Paneth cells, control microbiota composition and play a key role in intestinal barrier function…”
Get full text

Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn’s disease by KÜBLER, I., KOSLOWSKI, M. J., GERSEMANN, M., FELLERMANN, K., BEISNER, J., BECKER, S., ROTHFUSS, K., HERRLINGER, K. R., STANGE, E. F., WEHKAMP, J.

“…Summary Background  Crohn’s Disease (CD), a chronic intestinal inflammation, is currently treated primarily by therapeutics which are directed against…”
Get full text

Defensin pattern in chronic gastritis: HBD-2 is differentially expressed with respect to Helicobacter pylori status by Wehkamp, J, Schmidt, K, Herrlinger, K R, Baxmann, S, Behling, S, Wohlschläger, C, Feller, A C, Stange, E F, Fellermann, K

“…Background/Aims: Recent reports have suggested that Helicobacter pylori infection induces the mucosal antibiotic peptide human β defensin 2 (HBD-2). Therefore,…”
Get full text

6‐Thioguanine — efficacy and safety in chronic active Crohn's disease by Herrlinger, K. R., Kreisel, W., Schwab, M., Schoelmerich, J., Fleig, W. E., Ruhl, A., Reinshagen, M., Deibert, P., Fellermann, K., Greinwald, R., Stange, E. F.

“…Summary Background : Azathioprine and mercaptopurine are commonly used in chronic active Crohn's disease. They share the disadvantage of a delayed onset of…”
Get full text

Synergistic sedation with low-dose midazolam and propofol for colonoscopies by Reimann, F M, Samson, U, Derad, I, Fuchs, M, Schiefer, B, Stange, E F

“…Patients undergoing colonoscopy are often sedated with benzodiazepines and long-acting opiates. Since low-dose midazolam also acts synergistically with…”
Get more information

Innate immunity and colonic inflammation: Enhanced expression of epithelial α-defensins by WEHKAMP, J, SCHWIND, B, HERRLINGER, K. R, BAXMANN, S, SCHMIDT, K, DUCHROW, M, WOHLSCHLÄGER, C, FELLER, A. C, STANGE, E. F, FELLERMANN, K

“…Human alpha-defensins contribute to local intestinal host defense as part of innate immunity and may be of major relevance in microbial infection and chronic…”
Get full text

Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 Versus prednisolone in active crohn's disease by HERRLINGER, Klaus R, WITTHOEFT, Thomas, SCHWERTSCHLAG, Ulrich, SHAPIRO, Mark, STANGE, Eduard F, RAEDLER, Andreas, BOKEMEYER, Bernd, KRUMMENERL, Thomas, SCHULZKE, Jorg-Dieter, BOERNER, Norbert, KUEPPERS, Bruno, EMMRICH, Joerg, MESCHEDER, Axel

“…Interleukin-11 has shown benefit in animal inflammatory bowel disease models. Recently, recombinant human interleukin-11 (rhIL-11) has been observed to induce…”
Get full text

Biliary lipids, cholesterol and bile synthesis: different adaptive mechanisms to dietary cholesterol in lean and obese subjects by KLASS, D. M., BÜHRMANN, K., SAUTER, G., DEL PUPPO, M., SCHEIBNER, J., FUCHS, M., STANGE, E. F.

“…Summary Background  Increased biliary cholesterol secretion together with elevated cholesterol synthesis may predispose obese subjects to cholesterol gallstone…”
Get full text

Cyclosporine for induction of remission in Crohn's disease by McDonald, J W D, Feagan, B G, Jewell, D, Brynskov, J, Stange, E F, Macdonald, J K

“…Cyclosporine was first found to be an effective and well-tolerated immunosuppressive agent in organ transplant recipients, and subsequently in several…”
Get more information